Psoriasis

August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.

Patients with psoriatic arthritis and rheumatoid arthritis who were obese were shown to present with significantly lower quality of life (QOL) and worse disease activity than those with normal weight.

New users of infliximab and adalimumab who had moderate to severe psoriasis exhibited an increased risk of hospitalization due to serious infection compared with etanercept users, with use of ustekinumab conversely linked with a decreased risk.

Researchers investigated whether responses to questionnaires on psoriasis and atopic dermatitis prevalence remained consistent over time.

Low cardiorespiratory fitness among young adult men was significantly associated with an increased risk of psoriasis and psoriatic arthritis over 3 decades.

The new report may help explain why patients with psoriasis have a higher risk of cardiovascular problems.

Psoriasis is prevalent among more than 7.5 million adults in the United States, a new study says.

A new report suggests patients with persistent nail psoriasis may benefit from biologics like tildrakizumab.

Recent reports document new COVID-19 guidance for people with psoriatic disease, positive safety and efficacy results for guselkumab, and findings linking the C-Jun protein with psoriasis.

Alcohol abuse, obesity, and the use of systemic therapies instead of biologics were all linked with poor response among individuals with psoriasis.

Three biologics appeared to increase herpes zoster risk, but 2 other therapies were shown to lower the risk, according to a study of patients in a Taiwanese national database.

Results of a systematic review and meta-analysis point to higher rates of metabolic syndrome among patients with psoriatic arthritis.

Both conditions involve a genetic predisposition as well as immune pathways that are triggered by environmental factors.

A review detailed the initial steps taken into personalized therapeutic options for psoriatic arthritis.

Generalized pustular psoriasis (GPP) may have therapies in a few years; how patients define remission in psoriatic arthritis (PsA).

A case of a patient with untreated psoriasis and nonischemic dilated cardiomyopathy (NIDCM) prompted clinicians to encourage study of the rare combination of disease.

Updates from 2 recent medical meetings about links between the gut, psoriasis, and other skin disease, as well as the risk of COVID-19.

Psoriasis may be associated with an increased prevalence of type 1 diabetes (T1D).

Patients with psoriasis have a higher level of interleukin-30 (IL-30) than healthy patients, according to a recent study.

Each month of duration of 90% or more improvement in Psoriasis Are and Severity Index significantly impacted patient-reported outcomes in patients with psoriasis.

Egyptian dermatologists were asked about the effect of COVID‐19 on prescription patterns, appointment rescheduling, therapy decisions, and telemedicine use.

The long-term findings come from a subgroup analysis of 120 patients in Japan taking part in an extension of the 3-part, double-blind, randomized, controlled reSURFACE 1 trial.

If left untreated, patients with psoriatic arthritis (PsA) are at risk of irreversible joint damage, cardiovascular disease, and death. Some other conditions conflated with PsA include chronic eczema, seborrheic dermatitis, onychomycosis, lichen planus, and nodular prurigo.

Ilumya (tildrakizumab) was shown to be safe and effective in controlling moderate to severe psoriasis for adults through 5 years of treatment in a recent study.

A Taiwanese study revealed that attributes associated with polycystic ovary syndrome (PCOS) may increase the risks of those patients developing psoriasis as well.